About Us
Eureka Therapeutics is a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system with the goal of curing cancer.
Recent News
Renowned physician-scientist, David A. Scheinberg, MD, PhD, to join Scientific Advisory Board of Eureka Therapeutics
Our Science and Technology
Faster and safer immunotherapies that defeat cancer cells while minimizing side effects
Pipeline
Our pipeline encompasses T cell therapies targeting well-studied cancer specific antigens, e.g. testis antigens, mutated oncogenes, viral antigens. Our lead program for liver cancer, ET1402, is expected to enter Phase I in 2017.
Partnerships
Collaborations are a vital pillar of our strategy for developing first-in-class immunotherapy for solid tumors. We believe that collaboration is key to achieving a “cure for cancer.” We welcome partnership opportunities around our technology platforms and product pipeline.
Hiring Now!
Hiring Now!
